UNSPSC 51181626: Liothyronine hydrochloride

This classification denotes a generic primary tumor tnm finding with the molecular formula C15H12I3NO4.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier T66DHO0SET, chemically known as alanine, 3-(4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl)-, hydrochloride, l-, but more generally known as liothyronine hydrochloride, which bears US NIH Compound Identifier 71283. European Medicines Agency schedules liothyronine hydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08527MIG.

Most nations, for tariff purposes, schedule liothyronine hydrochloride under HS 29374000. SMILES: C1CC(C(CC1OC2C(CC(CC2I)C[C@@H](C(=O)O)N)I)I)O.CL.

UNSPSC 51181626 Liothyronine hydrochloride is a Commodity code for a synthetic thyroid hormone used in the treatment of hypothyroidism and thyroid cancer. State and local governments procure this pharmaceutical through health departments, correctional facilities, public hospitals, school district health clinics, and municipal healthcare programs. The drug is typically purchased in tablet or injectable formulations and supplied through competitive bid processes or cooperative purchasing agreements with established pharmaceutical distributors. Issuing bodies include state health agencies, county correction departments, city-operated health systems, and independent school districts with nursing staff.

The source provided contains no recent state and local contract opportunities under this code. Without posted RFP, RFQ, IFB, or ITB notices in the available record, geographic activity and representative recent solicitations cannot be determined.